| Income Statement | 2025-08-31 | 2025-05-31 | 2024-08-31 | |
|---|---|---|---|---|
| Total revenue | 7,894 | 44,056 | 12,588 | |
| Research and development | 86,120 | 78,096 | 55,481 | |
| General and administrative | 13,159 | 14,282 | 11,718 | |
| Total operating expenses | 99,279 | 92,378 | 67,199 | |
| Loss from operations | -91,385 | -48,322 | -54,611 | |
| Interest and other income, net | 4,964 | 5,618 | 5,737 | |
| Loss before income taxes | -86,421 | -42,704 | -48,874 | |
| Provision for income taxes | 0 | 760 | 82 | |
| Net loss | -86,421 | -43,464 | -48,956 | |
| Net loss per share, basic (in usd per share) | -1.03 | -0.52 | -0.67 | |
| Net loss per share, diluted (in usd per share) | -1.03 | -0.52 | -0.67 | |
| Weighted-average number of shares outstanding, basic (in shares) | 84,159,336 | 83,882,477 | 72,779,381 | |
| Weighted-average number of shares outstanding, diluted (in shares) | 84,159,336 | 83,882,477 | 72,779,381 | |
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)